4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Multiple Organ Failure: new trials by email Literature Review of Multiple Organ Failure trials Research Report on Multiple Organ Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Metabolic Resuscitation for Septic Shock Best Practice, early metabolic resuscitation - Multiple Organ Failure, Septic Shock | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2019-10-04 | 2024-10-29 |
| The Val-CARD Trial Sodium Valproate - Cardiac Valve Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Terminated | University of Leicester | 45 | 2018-11-06 | 2026-08-17 |
| Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA Interferon Beta-1A, Placebo - Preventive Medicine, Multi Organ Failure | Phase 2 | Terminated | Faron Pharmaceuticals Ltd | 40 | 2017-02-18 | 2021-01-14 |
| Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 LB1148, Placebo - Septic Shock | Phase 2 | Terminated | Leading BioSciences, Inc | 8 | 2015-04-01 | 2020-06-01 |
Sepsis (2) · Shock, Septic (2) · Coronary Artery Disease (1) · Heart Valve Diseases (1) · Hyperlactatemia (1) · Infections (1) · Shock (1) · Systemic Inflammatory Response Syndrome (1) · Toxemia (1)
Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Shock (3) · Inflammation (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Heart Diseases (1) · Infections (1) · Metabolic Diseases (1) · Myocardial Ischemia (1) · Nutritional and Metabolic Diseases (1) · Signs and Symptoms (1) · Systemic Inflammatory Response Syndrome (1)
Drugs, Investigational (1) · Glucose (1) · Interferon beta-1a (1) · Parenteral Nutrition (1) · Practice Guidelines as Topic (1) · Proteins (1) · Standard of Care (1) · Tranexamic Acid (1) · Valproic Acid (1)
Faron Pharmaceuticals Ltd (1) · Leading BioSciences, Inc (1) · M.D. Anderson Cancer Center (1) · University of Leicester (1)
United States (2) · Canada (1) · Estonia (1) · Finland (1) · Lithuania (1) · United Kingdom (1)
Gavin Murphy, MD (1) · Harri Hakovirta, MD (1) · Joseph L. Nates, MBA,MD (1) · Maarit Venermo, MD (1) · Marius Roman, MD (1) · Tom Hallam, PhD (1)
2014 (1), 2018 (1), P30CA016672 (1)